arrow
M

Michael Boyer

University of Sydney
H指数:79
被引数:5.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Amivantamab联合化疗与化疗一线治疗EGFR外显子20插入突变的晚期非小细胞肺癌患者: PAPILLON Asia亚组分析

2026-02-020
PRE
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

Amivantamab在晚期NSCLC和MET外显子14跳跃突变参与者中的应用: CHRYSALIS研究的最终结果

2025-05-160
PREAI
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
2024-07-010
OA
Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer

澳大利亚老年不可切除的III期非小细胞肺癌患者放化疗后巩固durvalumab的真实世界疗效和毒性

2024-03-015
OA
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study
2024-02-074
OAAI
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
2023-11-3091
PRE
Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice
2023-05-1112
OAAI